eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer

Prostate cancer (PCa) is one of the most commonly diagnosed cancers in males worldwide. lncRNAs (long noncoding RNAs) play a significant role in the occurrence and development of PCa. eRNAs (enhancer RNAs) and SE-lncRNAs (superenhancer lncRNAs) are important elements of lncRNAs, but the role of eRNA...

Full description

Saved in:
Bibliographic Details
Published in:Disease markers 2020, Vol.2020 (2020), p.1-17
Main Authors: Han, Junsong, Chen, Xue, Xu, Yi, Li, Huili, Cao, Qunfa, Jiang, Min, Pang, Panpan, Zhang, Xiaona, Li, Yao
Format: Article
Language:English
Subjects:
Biomarkers
Chromatin
Data analysis
Design
DNA microarrays
Gene expression
Gene regulation
Genes
Genetic transcription
Genomes
Hybridization
Instrument industry
Mediation
Medical treatment
Prostate cancer
Software
Transcription
Transcription factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer (PCa) is one of the most commonly diagnosed cancers in males worldwide. lncRNAs (long noncoding RNAs) play a significant role in the occurrence and development of PCa. eRNAs (enhancer RNAs) and SE-lncRNAs (superenhancer lncRNAs) are important elements of lncRNAs, but the role of eRNAs and SE-lncRNAs in PCa remains largely unclear. In this work, we identified 681 eRNAs and 292 SE-lncRNAs that were expressed differentially in PCa using a microarray. We also found that eRNAs transcribed from active open chromatin had significantly higher expression than those from active closed chromatin, and SE-lncRNAs had a little higher expression than eRNAs. Next, we constructed a transcriptional regulation network that eRNA-related enhancer and the target genes shared the same TF-binding motifs. Further, we investigated whether CTCF played a role in mediating the transcriptional regulation network. eRNAs, especially those that regulate androgen response genes, may be candidates for prognostic biomarkers and therapy targets. Our work provides a new perspective for developing medical treatments and therapies for prostate cancer.
ISSN:0278-0240
1875-8630
DOI:10.1155/2020/8847986